From: Breast Cancer Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Subtype | Treatment Options | Comments |
---|---|---|
Luminal A–like | ||
– Hormone receptor–positive | Endocrine therapy alone in most cases | Consider chemotherapy if: |
– HER2-negative | – High tumor burden (≥4 LNs, T3 or higher) | |
– PR >20% | ||
– Ki67 low | – Grade 3 | |
Luminal B–like | ||
– Hormone receptor–positive | Endocrine therapy plus chemotherapy in most cases | |
– HER2-negative | ||
– Either Ki67 high or PR low | ||
HER2-positive | Chemotherapy plus anti-HER2 therapy | Use endocrine therapy if also hormone receptor–positive |
May consider omitting chemotherapy plus anti-HER2 for small node-negative tumors | ||
Triple-negative | Chemotherapy | May consider omitting chemotherapy for small node-negative tumors |
HER2 = human epidermal growth factor receptor 2; LN = lymph node; PR = progesterone receptor.
aModified from Senkus et al.[82]
From: Breast Cancer Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.